TNX-1500 + Placebo: USP 0.9% sterile saline for injection + Keyhole Limpet Hemocyanin (KLH)
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phase 1 First-in-human Study Involving Healthy Subjects
Conditions
Phase 1 First-in-human Study Involving Healthy Subjects
Trial Timeline
Jul 18, 2023 → Feb 22, 2024
NCT ID
NCT07473752About TNX-1500 + Placebo: USP 0.9% sterile saline for injection + Keyhole Limpet Hemocyanin (KLH)
TNX-1500 + Placebo: USP 0.9% sterile saline for injection + Keyhole Limpet Hemocyanin (KLH) is a phase 1 stage product being developed by Tonix Pharmaceuticals for Phase 1 First-in-human Study Involving Healthy Subjects. The current trial status is completed. This product is registered under clinical trial identifier NCT07473752. Target conditions include Phase 1 First-in-human Study Involving Healthy Subjects.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07473752 | Phase 1 | Completed |
Competing Products
20 competing products in Phase 1 First-in-human Study Involving Healthy Subjects
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Tamsulosin HCl + Solifenacin Succinate + EC905 | Astellas Pharma | Phase 1 | 33 |
| solifenacin succinate + mirabegron + mirabegron/solifenacin succinate | Astellas Pharma | Phase 1 | 33 |
| Graceptor® | Astellas Pharma | Pre-clinical | 23 |
| Lemborexant + Placebo | Eisai | Approved | 85 |
| BIW-8962 | Kyowa Kirin | Phase 1/2 | 41 |
| Acalabrutinib | AstraZeneca | Phase 1/2 | 41 |
| Sacituzumab tirumotecan | Merck | Phase 2 | 52 |
| progesterone + Progesterone | Merck | Approved | 85 |
| Asciminib | Novartis | Pre-clinical | 23 |
| Nilotinib | Novartis | Phase 3 | 77 |
| Imatinib mesylate | Novartis | Phase 3 | 77 |
| Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib Mesylate | Novartis | Phase 3 | 77 |
| ribociclib + Trametinib | Novartis | Phase 1 | 33 |
| Nilotinib | Novartis | Approved | 85 |
| Imatinib | Novartis | Phase 3 | 77 |
| Nilotinib | Novartis | Approved | 85 |
| Gleevec | Novartis | Phase 2 | 52 |
| Nilotinib + Ruxolitinib | Novartis | Phase 1/2 | 41 |
| ABL001 | Novartis | Phase 3 | 77 |